MX2018012866A - Composiciones y metodos para generar anticuerpos basado en el uso de un locus potenciador de la expresion. - Google Patents
Composiciones y metodos para generar anticuerpos basado en el uso de un locus potenciador de la expresion.Info
- Publication number
- MX2018012866A MX2018012866A MX2018012866A MX2018012866A MX2018012866A MX 2018012866 A MX2018012866 A MX 2018012866A MX 2018012866 A MX2018012866 A MX 2018012866A MX 2018012866 A MX2018012866 A MX 2018012866A MX 2018012866 A MX2018012866 A MX 2018012866A
- Authority
- MX
- Mexico
- Prior art keywords
- expression
- methods
- compositions
- antibodies based
- making antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Analytical Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662325385P | 2016-04-20 | 2016-04-20 | |
| PCT/US2017/028552 WO2017184831A1 (en) | 2016-04-20 | 2017-04-20 | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018012866A true MX2018012866A (es) | 2019-03-11 |
Family
ID=58701850
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018012866A MX2018012866A (es) | 2016-04-20 | 2017-04-20 | Composiciones y metodos para generar anticuerpos basado en el uso de un locus potenciador de la expresion. |
| MX2024014381A MX2024014381A (es) | 2016-04-20 | 2018-10-19 | Composiciones y metodos para generar anticuerpos basado en el uso de un locus potenciador de la expresion |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024014381A MX2024014381A (es) | 2016-04-20 | 2018-10-19 | Composiciones y metodos para generar anticuerpos basado en el uso de un locus potenciador de la expresion |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11530277B2 (enExample) |
| EP (1) | EP3445780A1 (enExample) |
| JP (3) | JP7134868B2 (enExample) |
| KR (2) | KR102474757B1 (enExample) |
| CN (2) | CN109071633B (enExample) |
| AR (1) | AR108295A1 (enExample) |
| AU (2) | AU2017253240B2 (enExample) |
| BR (1) | BR112018071285A2 (enExample) |
| CA (1) | CA3015371A1 (enExample) |
| EA (1) | EA201892137A1 (enExample) |
| IL (2) | IL262268B2 (enExample) |
| MX (2) | MX2018012866A (enExample) |
| SG (2) | SG10202010156XA (enExample) |
| TW (1) | TW201803981A (enExample) |
| WO (1) | WO2017184831A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202010156XA (en) | 2016-04-20 | 2020-11-27 | Regeneron Pharma | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
| IL275462B2 (en) * | 2017-12-22 | 2026-01-01 | Genentech Inc | Targeted integration of nucleic acids |
| WO2020034097A1 (en) | 2018-08-14 | 2020-02-20 | Wuxi Biologics (Shanghai) Co., Ltd. | Transcriptional regulatory element and its use in enhancing the expression of exogenous protein |
| KR102559149B1 (ko) | 2018-10-26 | 2023-07-24 | 에프. 호프만-라 로슈 아게 | 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법 |
| CN113631711B (zh) * | 2018-12-21 | 2025-03-04 | 豪夫迈·罗氏有限公司 | 核酸的靶向整合 |
| KR20210134932A (ko) * | 2019-03-29 | 2021-11-11 | 에프. 호프만-라 로슈 아게 | 정의된 조직에서 다중 발현 카세트의 표적화된 통합에 의해 FcRn 발현 세포를 생성하는 방법 |
| EP3950938A4 (en) | 2019-04-02 | 2023-01-18 | Chugai Seiyaku Kabushiki Kaisha | PROCEDURE FOR INTRODUCING A TARGET-SPECIFIC ALIEN |
| BR112021025425A2 (pt) * | 2019-06-19 | 2022-02-01 | Hoffmann La Roche | Método para produzir uma célula de mamífero recombinante e uso de mrna de recombinase cre |
| CA3140323A1 (en) * | 2019-06-19 | 2020-12-24 | Johannes Auer | Method for the generation of a multivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
| MX2021015648A (es) | 2019-06-19 | 2022-02-03 | Hoffmann La Roche | Metodo para la generacion de una celula que expresa un anticuerpo multiespecifico multivalente mediante integracion dirigida de multiples casetes de expresion en una organizacion definida. |
| KR20220010019A (ko) * | 2019-06-19 | 2022-01-25 | 에프. 호프만-라 로슈 아게 | 정의된 조직에서 다중 발현 카세트의 표적화된 통합에 의해 2가 이중특이성 항체 발현 세포를 생성하는 방법 |
| CA3140287A1 (en) * | 2019-06-19 | 2020-12-24 | Johannes Auer | Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
| AU2020308002A1 (en) * | 2019-06-26 | 2022-01-20 | Genentech, Inc. | Randomized configuration targeted integration of nucleic acids |
| CN115335517A (zh) * | 2020-01-10 | 2022-11-11 | 豪夫迈·罗氏有限公司 | 用于从短片段组装大核酸的方法 |
| EP4453227A1 (en) * | 2021-12-22 | 2024-10-30 | Genentech, Inc. | Multi-vector recombinase mediated cassette exchange |
| CN121794393A (zh) | 2023-09-07 | 2026-04-03 | 里珍纳龙药品有限公司 | 经共价表面修饰的腺相关病毒的生产和纯化 |
| CN119955730A (zh) * | 2023-11-08 | 2025-05-09 | 深圳太力生物技术有限责任公司 | 一种细胞株及其制备方法与应用 |
| TW202540433A (zh) | 2023-11-21 | 2025-10-16 | 美商再生元醫藥公司 | 藉由活體外接合產生共價表面修飾之腺相關病毒及共價表面修飾的腺相關病毒之純化 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6800457B2 (en) | 1998-09-22 | 2004-10-05 | Bristol-Myers Squibb Company | Expression vectors containing hot spot for increased recombinant protein expression in transfected cells |
| KR100781481B1 (ko) | 2000-08-07 | 2007-12-03 | 세로노 제네틱스 인스티튜트 에스.에이. | 정신분열증 관련된 유전자와 단백질 |
| GB0209884D0 (en) | 2002-04-30 | 2002-06-05 | Ares Trading Sa | Proteins |
| AU2003237259B2 (en) | 2002-05-29 | 2008-01-24 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
| CA2504595A1 (en) | 2002-11-14 | 2004-06-03 | Lynne Krummen | Intron fusion construct and method of using for selecting high-expressing production cell lines |
| CN101198698B (zh) | 2005-03-31 | 2014-03-19 | 中外制药株式会社 | 通过调节多肽缔合制备多肽的方法 |
| WO2007110205A2 (en) | 2006-03-24 | 2007-10-04 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| NZ587107A (en) | 2006-06-02 | 2012-05-25 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| WO2008079943A2 (en) | 2006-12-21 | 2008-07-03 | Smithkline Beecham Corporation | Novel methods |
| US20080216185A1 (en) | 2007-01-19 | 2008-09-04 | Invitrogen Corporation | Compositions and Methods for Genetic Manipulation and Monitoring of Cell Lines |
| CN104497143B (zh) | 2007-03-29 | 2020-08-25 | 健玛保 | 双特异性抗体及其制造方法 |
| WO2008151219A1 (en) * | 2007-06-04 | 2008-12-11 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| US8409838B2 (en) | 2009-06-02 | 2013-04-02 | Regeneron Pharmaceuticals, Inc. | Fucosylation-deficient cells |
| LT2975051T (lt) | 2009-06-26 | 2021-07-12 | Regeneron Pharmaceuticals, Inc. | Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu |
| MX2012003396A (es) | 2009-09-16 | 2012-04-10 | Genentech Inc | Complejos de proteina conteniendo helice super-enrollada y/o enlazador tether y usos de los mismos. |
| JP6040148B2 (ja) | 2010-04-20 | 2016-12-07 | ゲンマブ エー／エス | ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法 |
| AU2011290480B2 (en) | 2010-08-16 | 2015-07-30 | Novimmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
| PT3865581T (pt) | 2011-08-05 | 2024-10-04 | Regeneron Pharma | Murganhos da cadeia leve universal humanizada |
| TWI641687B (zh) | 2012-05-29 | 2018-11-21 | 美商再生元醫藥公司 | 生產細胞株增強子 |
| EP2711428A1 (en) | 2012-09-21 | 2014-03-26 | Lonza Biologics plc. | Site-specific integration |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TW202423993A (zh) | 2012-11-14 | 2024-06-16 | 美商再生元醫藥公司 | 重組細胞表面捕捉蛋白質 |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| US20140308285A1 (en) | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
| TWI670283B (zh) | 2013-12-23 | 2019-09-01 | 美商建南德克公司 | 抗體及使用方法 |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| MX2017005306A (es) * | 2014-10-23 | 2018-01-09 | Regeneron Pharma | Novedosos sitios de integracion en celulas cho y usos de estos. |
| KR102777500B1 (ko) | 2015-09-23 | 2025-03-11 | 리제너론 파아마슈티컬스, 인크. | 최적화된 항-cd3 이중특이적 항체 및 이의 용도 |
| SG10202010156XA (en) | 2016-04-20 | 2020-11-27 | Regeneron Pharma | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
-
2017
- 2017-04-20 SG SG10202010156XA patent/SG10202010156XA/en unknown
- 2017-04-20 EA EA201892137A patent/EA201892137A1/ru unknown
- 2017-04-20 IL IL262268A patent/IL262268B2/en unknown
- 2017-04-20 CA CA3015371A patent/CA3015371A1/en active Pending
- 2017-04-20 TW TW106113300A patent/TW201803981A/zh unknown
- 2017-04-20 US US16/095,067 patent/US11530277B2/en active Active
- 2017-04-20 CN CN201780024560.2A patent/CN109071633B/zh active Active
- 2017-04-20 AR ARP170101018A patent/AR108295A1/es unknown
- 2017-04-20 EP EP17723182.6A patent/EP3445780A1/en active Pending
- 2017-04-20 JP JP2018552822A patent/JP7134868B2/ja active Active
- 2017-04-20 SG SG11201807881VA patent/SG11201807881VA/en unknown
- 2017-04-20 BR BR112018071285A patent/BR112018071285A2/pt not_active Application Discontinuation
- 2017-04-20 CN CN202211344339.4A patent/CN116004544A/zh active Pending
- 2017-04-20 AU AU2017253240A patent/AU2017253240B2/en active Active
- 2017-04-20 MX MX2018012866A patent/MX2018012866A/es unknown
- 2017-04-20 WO PCT/US2017/028552 patent/WO2017184831A1/en not_active Ceased
- 2017-04-20 KR KR1020217035334A patent/KR102474757B1/ko active Active
- 2017-04-20 KR KR1020187029371A patent/KR20180134894A/ko not_active Ceased
-
2018
- 2018-10-19 MX MX2024014381A patent/MX2024014381A/es unknown
-
2022
- 2022-08-31 JP JP2022137796A patent/JP7546015B2/ja active Active
- 2022-11-10 US US18/054,350 patent/US12503520B2/en active Active
-
2023
- 2023-12-04 IL IL309065A patent/IL309065B1/en unknown
-
2024
- 2024-08-26 JP JP2024144352A patent/JP7789143B2/ja active Active
- 2024-09-26 AU AU2024220126A patent/AU2024220126A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024014381A (es) | Composiciones y metodos para generar anticuerpos basado en el uso de un locus potenciador de la expresion | |
| MX2025003852A (es) | Composiciones y metodos para generar anticuerpos basado en el uso de loci potenciadores de expresion | |
| ZA202201361B (en) | Methods and compositions comprising purified recombinant polypeptides | |
| ZA202308519B (en) | Anti-vegf protein compositions and methods for producing the same | |
| PH12018501456A1 (en) | Chimeric proteins and methods of regulating gene expression | |
| EA201792420A1 (ru) | Композиции и способы перепрограммирования tcr с помощью гибридных белков | |
| MY199937A (en) | Steroids and protein-conjugates thereof | |
| EP4279136A3 (en) | Methods for determining car-t cells dosing | |
| MX2021010668A (es) | Proteinas de fusion de citoquinas. | |
| EP4368702A3 (en) | Method of enhancing rna expression in a cell | |
| PH12018502361B1 (en) | Gdf15 fusion proteins and uses thereof | |
| WO2019123294A3 (en) | Pyrazolo piperidine and pyrazolo pyrimidine derivatives for the treatment of neuropsychiatric systemic lupus erythematosus | |
| EA201791275A1 (ru) | Способы получения ctp-модифицированных полипептидов длительного действия | |
| MY183188A (en) | Non-human animals having a humanized b-cell activating factor gene | |
| MX2015012168A (es) | Expansión de celulas madre adultas in vitro. | |
| EA201892588A1 (ru) | Прямой отбор клеток, экспрессирующих высокие уровни гетеромерных белков, с использованием глутаминсинтетазных векторов внутригенной комплементации | |
| EP3543335A3 (en) | Soluble intein fusion proteins and methods for purifying biomolecules | |
| EA201791918A1 (ru) | Модификация белков клеток-хозяев | |
| MX2015014424A (es) | Construcciones de proteinas mitocondriales y sus usos. | |
| MX2020001223A (es) | Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas. | |
| WO2016011448A3 (en) | Methods and compositions for expression of polypeptides in a cell | |
| EP4467565A3 (en) | Anti-tnf alpha antibody formulations | |
| TN2016000140A1 (en) | Recombinant glycoproteins and uses thereof. | |
| MX2021009154A (es) | Selectividad eficaz de proteinas recombinantes. | |
| WO2017079656A3 (en) | Artificial proteins and compositions and methods thereof |